SOURCE: Barrier Therapeutics, Inc.

June 06, 2007 16:05 ET

Barrier Therapeutics Introduces New 50g-Size Tube of Vusion® Ointment

PRINCETON, NJ--(Marketwire - June 6, 2007) - Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that it has launched a new 50g-size tube of its Vusion® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment. Vusion Ointment is the only prescription product approved in the U.S. for the treatment of diaper dermatitis, also known as diaper rash, complicated with a documented fungal infection caused by yeast known as Candida.

"We are pleased to offer this larger 50g tube size in response to physician requests and as part of our strategic plan announced last month to optimize the value of this brand," said Al Altomari, Chief Operating Officer of Barrier Therapeutics.

In March 2007, the company entered into an agreement with Novartis Consumer Health, Inc. whereby Novartis Consumer Health is promoting Vusion Ointment to pediatricians in the U.S. Novartis Consumer Health began promoting Vusion Ointment in May 2007, supplementing the efforts of Barrier Therapeutics' 60-person sales force.

About Vusion Ointment and Diaper Dermatitis Complicated by Documented Candidiasis (DDCC)

Vusion Ointment is specifically formulated for the treatment of DDCC in immunocompetent infants and children four weeks and older. Vusion is a steroid-free formulation that contains the active ingredient miconazole nitrate at a concentration of 0.25%, which directly treats the infection with proven antifungal efficacy. The ointment base for Vusion is comprised of zinc oxide and white petrolatum, which are the main components in most common diaper rash products. In clinical trials, Vusion showed statistically significant improvement within three days of treatment in infants with DDCC.

DDCC occurs when diaper dermatitis is complicated with a fungal infection caused by yeast known as Candida. The existence of Candida is readily determined by microscopic evaluation for presence of pseudohyphae or budding yeast. There are approximately eight million infants under the age of two in the U.S., and it is estimated that diaper dermatitis is observed in approximately one million pediatric outpatient visits each year. Of the diaper dermatitis cases treated by physicians, it is estimated that more than 40 percent are complicated by the yeast Candida. Until the FDA approved Vusion Ointment, common treatment options included the use of antifungal products, steroids, and combination products not specifically approved for the treatment of DDCC or for use on infants.

For more information on Vusion Ointment, please call 1-866-440-5508 or visit the product website at www.vusionointment.com. For full prescribing information, please visit www.vusionointment.com.

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.

Safe Harbor Statement

In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Barrier's current expectations or forecasts of future events including statements regarding optimizing the value of the Vusion brand. Barrier's performance and financial results could differ materially from those reflected in these forward-looking statements due to the marketplace acceptance of Barrier's products, Barrier's ability to execute its commercial and clinical strategy, the decisions of regulatory authorities, the results of clinical trials and strategic decisions regarding its pipeline, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements, please see the risk factors in the company's Quarterly Report on Form 10-Q for the period ended March 31, 2007 which is on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Barrier undertakes no obligation to update publicly any forward-looking statement.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    EVP & CFO
    (609) 945-1202

    Lazar Partners Ltd.
    Gregory Gin
    Investor Relations
    (212) 867-1762